MoonLake Immunotherapeutics (MLTX) stock intrinsic value fair value estimate & owner earnings analysis

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company with no approved product and no product sales. Its business is built around a single drug candidate, sonelokimab, a tri-specific antibody-like molecule being tested in several inflammatory and autoimmune conditions, most importantly hidradenitis suppurativa (a painful chronic skin disease) and psoriatic arthritis. Because no product has been approved anywhere, we place no value on the drug itself or on any future product revenue. What we do value is the company's cash, net of debt and net of the money it will keep spending while it pursues approval. As of its most recent reported quarter (June 30, 2026), MoonLake held roughly $530 million in cash and short-term investments against about $100 million of secured term debt from its lender, Hercules Capital, for net liquid resources of a little over $430 million. That debt carries an interest rate near 8.5%-9%, well above ordinary long-term borrowing costs, and is secured against essentially all of the company's assets; we account for its above-market cost by treating it as slightly more burdensome than its face amount. The company also owes its original licensor, Merck Healthcare KGaA, up to roughly $300 million in milestone payments, but these only come due if and when regulatory filings are accepted and the drug is sold commercially, so they reduce the payoff from a future approval rather than today's cash pile. Bringing the June 30 balance forward for roughly one more quarter of spending, and dividing by approximately 74 million diluted shares, gives a current net-cash value of a bit under $5 per share before any further deductions. We reduce that figure in every case to reflect cash that will keep being spent, with zero credit given for what it buys, since nothing has been approved. The three cases differ mainly in how much of that spending, and on what terms, we think is realistic: The bear case reflects a specific, already-disclosed setback: in September 2025, MoonLake reported that of its two identically designed pivotal trials in hidradenitis suppurativa, one (VELA-2) narrowly missed its own pre-agreed statistical test at 16 weeks because of an unusually high response in patients taking placebo, even though the underlying treatment effect looked similar to the trial that succeeded. The company's own lender treated this as a real setback, immediately cutting $175 million of loan capacity that had been tied to a clean pass on both trials. If the ongoing psoriatic-arthritis trials or the not-yet-started trial in a related skin condition (PPP) run into similar trouble, or if regulators are unwilling to accept the mixed hidradenitis suppurativa results, MoonLake would likely need years more of funding with no offsetting revenue and would probably have to raise money on less attractive terms. This case values the shares at what would likely remain after roughly a year of committed spending, net of debt. The base case takes the September 2025 results at face value: a mixed but, on balance, supportive readout, since both trials showed a consistent, clinically meaningful effect and differed mainly on a statistical technicality tied to one trial's unusual placebo response. Absent a formal approval, we still credit nothing for the pipeline, but assume the company continues to fund its ongoing trials for the next several quarters without a major additional setback. The bull case gives credit only to what is already contractually true: the company's psoriatic-arthritis trials have not (as of this writing) run into the kind of complication that affected the hidradenitis suppurativa program, and clearing that hurdle cleanly would unlock further loan capacity on favorable, already-agreed terms and step down the interest rate on existing debt. That preserves more of today's cash for shareholders. We still assign no value to eventual product revenue itself. As of the 2025 annual report, MoonLake said its cash, short-term investments and available loan capacity would fund operations into the second half of 2027; it has since raised substantial further capital in the first half of 2026, extending that runway further. There is no unusual doubt about the company's ability to continue operating over the next year, and it reported being in compliance with its loan covenants as of its last annual report. This valuation deliberately gives no credit for the drug working. The margin-of-safety price is set at a meaningful discount to the base-case, cash-based estimate, to allow for the scenario where additional trial or regulatory setbacks force years of further, more dilutive fundraising.